Human Papillomavirus (HPV), High Risk by PCR, SurePath (INACTIVE as of 05/18/20: Refer to 2011933 in the May Hotline)
FDA-approved test for routine cervical cancer screening in combination with cervical cytology (Pap smear) in women ≥30 years. Follow-up test for abnormal cytology results in women ≥21 years.
Qualitative Polymerase Chain Reaction
Mon, Wed, Fri
Cervical, anal or vaginal specimens with SurePath collection kit and place in SurePath media.
Mix well. Transfer 3 mL to an ARUP Standard Transport Tube. (Min 1.5 mL)
Bloody or dark brown specimens. Specimens in any media other than indicated above.
Specimen source required.
Ambient: 1 month; Refrigerated: 6 months; Frozen: Unacceptable
This test amplifies DNA of 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) associated with cervical cancer and its precursor lesions. Sensitivity may be affected by specimen collection methods, stage of infection, and the presence of interfering substances. Results should be interpreted in conjunction with other available laboratory and clinical data. A negative high-risk HPV result does not exclude the presence of other high-risk HPV types, the possibility of future cytologic abnormalities, underlying CIN2-3, or cancer.
This test is intended for medical purposes only and is not valid for the evaluation of suspected sexual abuse or for other forensic purposes. HPV testing should not be used for screening or management of atypical squamous cells of undetermined significance (ASCUS) in women under age 21.
No compliance statements are in use for this test.
|Component Test Code*||Component Chart Name||LOINC|
|2011943||HPV High Risk by PCR, SurePath||49896-4|
- HPV High Risk
- HPV HR SurePath
- Human papilloma virus